Dexcom
Eli Lilly’s Tempo Pen and connected Tempo Smart Button will integrate with the software platforms and/or medical devices offered by the diabetes management companies.
As of Friday afternoon, Dexcom’s stock has fallen 6.3% from about $422 to $395.
Also: Dexcom promotes Jereme Sylvain to EVP and CFO; Amalgam Rx snags CMS' Jennifer Main as COO and CFO.
The fund will be zeroing in on sensing tech, data analytics, remote patient monitoring and population health.
The company attributes volume growth, new patient additions and increasing awareness of real-time continuous glucose monitoring to its revenue growth.
In a J P. Morgan virtual talk, CEO Jason Gorevic said the programs have either already kicked off or will be launching later this year.
Also: Dexcom continues to make strides, while iRhythm Technologies takes a hit in Q2.
Some of Dexcom’s G6 applicators were getting stuck to the wearable CGM, but the company said it has worked to remedy this issue.